

30 April 2014

TENDER RESULTS

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012 and 2013/14 Invitation to Tender, dated 07 November 2013.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12th of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – <http://www.pharmac.health.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

CORRECTION to MARCH 2014 tender notification: in **bold** and strikethrough

1. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Acetazolamide	Tab 250 mg; 100 tablets, bottle	\$17.03	\$17.03	Diamox (Aspen)	1%	1 July 2014	1 October 2014 1 September 2014

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Fusidic acid	crm 2%; 15 g OP, tube	\$3.25	\$2.52	DP Fusidic Acid Cream (Douglas)	1 November 2014	1 January 2015	1 April 2015	Foban (AFT)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Fusidic acid	crm 2%; 15 g, tube	\$3.25	\$2.52	DP Fusidic Acid Cream (Douglas)	1%	1 November 2014	1 January 2015	Foban (AFT)

2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

4. Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Acitretin	cap 10 mg; 60 capsules, blister pack	\$38.66	\$17.86	Novatretin (Douglas)	1 September 2014	1 November 2014	1 February 2015	Neotigason (Actavis)
Acitretin	cap 25 mg; 60 capsules, blister pack	\$83.11	\$41.36	Novatretin (Douglas)	1 September 2014	1 November 2014	1 February 2015	Neotigason (Actavis)
Amoxicillin with clavulanic acid	tab 500 mg with clavulanic acid 125 mg; 20 tablets, blister pack	\$12.55 per 100 tablets	\$1.95 per 20 tablets	Augmentin (GSK)	1 September 2014	1 November 2014	1 February 2015	Curam Duo (Sandoz)
Ciprofloxacin	tab 500 mg; 28 tablets, blister pack	\$3.00 per 28 tablets	\$2.00 per 28 tablets	Cipflox (Mylan)	1 July 2014	1 September 2014	1 December 2014	Cipflox -100 tablet packsize (Mylan)
Ciprofloxacin	tab 750 mg; 28 tablets, blister pack	\$5.15	\$3.75	Cipflox (Mylan)	1 July 2014	1 September 2014	1 December 2014	Ciprofloxacin Rex (Rex Medical)
Cyproterone acetate with ethinyloestradiol ¹	tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets; 168 tablets, blister pack (6 x 21 active tablets and 6 x 7 placebo tablets, blister pack)	\$3.89 per 84 tablets	\$5.36 per 168 tablets	Ginet (Rex Medical)	1 October 2014	1 December 2014	1 March 2015	Ginet 84 tablet packsize (Rex Medical)
Gliclazide ²	tab 80 mg; 500 tablets, bottle	\$17.60	\$11.50	Glizide (Mylan)	1 September 2014	1 November 2014	1 February 2015	Apo-Gliclazide (Apotex)
Ibuprofen ³	tab 200 mg; 1,000 tablets, blister pack	\$12.75	\$9.45	Ibugesic (Rex Medical)	1 December 2014	1 February 2015	1 May 2015	Arrowcare (Actavis)

Chemical Name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Lamivudine	tab 100 mg; 28 tablets, blister pack	\$32.50	\$6.00	Zeffix (GSK)	1 September 2014	1 November 2014	1 February 2015	Zetlam (Mylan)
Nifedipine	tab long-acting 30 mg; 30 tablets, blister pack	\$8.56	\$3.75	Adefin XL (Mylan)	1 July 2014	1 September 2014	1 December 2014	Arrow-Nifedipine XR (Arrow) Adalat Oros (Bayer)
Nifedipine	tab long-acting 60 mg; 30 tablets, blister pack	\$12.28	\$5.75	Adefin XL (Mylan)	1 July 2014	1 September 2014	1 December 2014	Arrow-Nifedipine XR (Arrow) Adalat Oros (Bayer)
Pamidronate disodium	inj 3 mg per ml, 10 ml vial; 1 vial	\$16.00	\$6.80	Pamisol (Hospira)	1 July 2014	1 September 2014	1 December 2014	Pamidronate BNM (Boucher)
Pamidronate disodium	inj 6 mg per ml, 10 ml vial; 1 vial	\$32.00	\$13.20	Pamisol (Hospira)	1 July 2014	1 September 2014	1 December 2014	Pamidronate BNM (Boucher)
Pamidronate disodium	inj 9 mg per ml, 10 ml vial; 1 vial	\$48.00	\$19.20	Pamisol (Hospira)	1 July 2014	1 September 2014	1 December 2014	Pamidronate BNM (Boucher)
Paracetamol	oral liq 120 mg per 5 ml; 1,000 ml, bottle	\$2.21 per 500 ml	\$4.15 per 1,000 ml	Paracare (API)	1 August 2014	1 October 2014	1 January 2015	Ethics Paracetamol (Multichem)
Paracetamol	tab 500 mg; 1,000 tablets, blister pack	\$9.38	\$8.47	Pharmacare (API)	1 September 2014	1 November 2014	1 February 2015	Parafast (Actavis)
Potassium iodate	tab 253 mcg (150 mcg elemental iodine); 90 tablets, bottle	\$6.53	\$3.65	NeuroTabs (AFT)	1 October 2014	1 December 2014	1 March 2015	NeuroKare (Alaron)
Ranitidine	tab 150 mg; 500 tablets, blister pack	\$6.79 per 250 tablets	\$10.30 per 500 tablets	Ranitidine Relief (Mylan)	1 September 2014	1 November 2014	1 February 2015	Arrow-Ranitidine (Actavis)
Ranitidine	tab 300 mg; 500 tablets, blister pack	\$9.34 per 250 tablets	\$14.73 per 500 tablets	Ranitidine Relief (Mylan)	1 September 2014	1 November 2014	1 February 2015	Arrow-Ranitidine (Actavis)

Chemical Name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
<p>1. The PSO for cyproterone acetate with ethinyloestradiol- tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets will be increased from “up to 84” to “up to 168”</p> <p>2. A Brand Switch Fee of \$4.33 is payable for this product from 1 February 2015 until 1 May 2015</p> <p>3. The subsidy for Ibuprofen tab 400 mg and tab 600 mg will be reduced to the level of twice and three-times, respectively, the subsidy for ibuprofen 200 mg via the re-application of reference pricing from 1 February 2015</p>								

5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Ciprofloxacin	tab 250 mg; 28 tablets, blister pack	\$2.20	\$1.75	Cipflox (Mylan)	1 July 2014	1 October 2014
Exemestane	tab 25 mg; 30 tablets, blister pack	\$22.57	\$14.50	Aromasin (Pfizer)	1 July 2014	1 October 2014
Lamivudine	oral liq 5 mg per ml; 240 ml, bottle	\$90.00	\$270.00	Zeffix (GSK)	1 September 2014	1 December 2014
Paracetamol	oral liq 250 mg per 5 ml; 1,000 ml, bottle	\$6.70	\$4.35	Paracare Double Strength (API)	1 July 2014	1 October 2014
Pravastatin	tab 20 mg; 30 tablets, blister pack	\$5.44	\$3.45	Cholvastin (Douglas)	1 August 2014	1 November 2014
Pravastatin	tab 40 mg; 30 tablets, blister pack	\$9.28	\$6.36	Cholvastin (Douglas)	1 August 2014	1 November 2014
Rizatriptan	tab orodispersible 10 mg; 30 tablets, blister pack	\$18.00	\$8.10	Rizamelt (Mylan)	1 July 2014	1 October 2014
Zidovudine [AZT] with lamivudine	tab 300 mg with lamivudine 150 mg; 60 tablets, bottle	\$63.50	\$44.00	Alphapharm (Mylan)	1 July 2014	1 October 2014

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

6. Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Acitretin	cap 10 mg; 60 capsules, blister pack	\$38.66	\$17.86	Novatretin (Douglas)	1%	1 September 2014	1 November 2014	Neotigason (Actavis)
Acitretin	cap 25 mg; 60 capsules, blister pack	\$83.11	\$41.36	Novatretin (Douglas)	1%	1 September 2014	1 November 2014	Neotigason (Actavis)
Amoxicillin with clavulanic acid	tab 500 mg with clavulanic acid 125 mg; 20 tablets, blister pack	\$12.55 per 100 tablets	\$1.95 per 20 tablets	Augmentin (GSK)	1%	1 September 2014	1 November 2014	Curam Duo (Sandoz)
Ceftazidime	inj 1 g vial; 1 vial	\$3.25	\$1.55	Fortum (GSK)	1%	1 August 2014	1 October 2014	DBL Ceftazidime (Hospira)
Ceftazidime	inj 2 g vial; 1 vial	\$6.49	\$3.34	Fortum (GSK)	1%	1 August 2014	1 October 2014	DBL Ceftazidime (Hospira)
Cefuroxime	inj 750 mg vial; 5 vials	\$6.96	\$3.70	Zinacef (GSK)	1%	1 September 2014	1 November 2014	m-Cefuroxime (Multichem)
Cefuroxime	inj 1.5g vial; 1 vial	\$2.65	\$1.30	Zinacef (GSK)	1%	1 September 2014	1 November 2014	Mylan (Mylan)
Gliclazide	tab 80 mg; 500 tablets, bottle	\$17.60	\$11.50	Glizide (Mylan)	1%	1 September 2014	1 November 2014	Apo-Gliclazide (Apotex)
Lamivudine	tab 100 mg; 28 tablets, blister pack	\$32.50	\$6.00	Zeffix (GSK)	1%	1 September 2014	1 November 2014	Zetlam (Mylan)
Nifedipine	tab long-acting 30 mg; 30 tablets, blister pack	\$8.56	\$3.75	Adefin XL (Mylan)	1%	1 July 2014	1 September 2014	Arrow-Nifedipine XR (Arrow)
Nifedipine	tab long-acting 60 mg; 30 tablets, blister pack	\$12.28	\$5.75	Adefin XL (Mylan)	1%	1 July 2014	1 September 2014	Arrow-Nifedipine XR (Arrow)
Pamidronate disodium	inj 3 mg per ml, 10 ml vial; 1 vial	\$16.00	\$6.80	Pamisol (Hospira)	1%	1 July 2014	1 September 2014	Pamidronate BNM (Boucher)

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Pamidronate disodium	inj 6 mg per ml, 10 ml vial; 1 vial	\$32.00	\$13.20	Pamisol (Hospira)	1%	1 July 2014	1 September 2014	Pamidronate BNM (Boucher)
Pamidronate disodium	inj 9 mg per ml, 10 ml vial; 1 vial	\$48.00	\$19.20	Pamisol (Hospira)	1%	1 July 2014	1 September 2014	Pamidronate BNM (Boucher)
Paracetamol	inj 10 mg per ml, 50 ml vial; 12 vials	\$22.50	\$12.90	Perfalgan (BMS)	1%	1 July 2014	1 September 2014	Paracetamol-AFT (AFT)
Paracetamol	inj 10 mg per ml, 100 ml vial; 12 vials	\$22.50	\$12.90	Perfalgan (BMS)	1%	1 July 2014	1 September 2014	Paracetamol-AFT (AFT)
Paracetamol	oral liq 120 mg per 5 ml; 1,000 ml, bottle	\$2.21 per 500 ml	\$4.15- per 1,000 ml	Paracare (API)	20%	1 August 2014	1 October 2014	Ethics Paracetamol (Multichem)
Ranitidine	tab 150 mg; 500 tablets, blister pack	\$6.79 per 250 tablets	\$10.30 per 500 tablets	Ranitidine Relief (Mylan)	1%	1 September 2014	1 November 2014	Arrow-Ranitidine (Actavis)
Ranitidine	tab 300 mg; 500 tablets, blister pack	\$9.34 per 250 tablets	\$14.73 per 500 tablets	Ranitidine Relief (Mylan)	1%	1 September 2014	1 November 2014	Arrow-Ranitidine (Actavis)
Remifentanil hydrochloride	inj 1 mg vial; 5 vials	\$27.95	\$10.00	Ultiva (GSK)	1%	1 September 2014	1 November 2014	Remifentanil-AFT (AFT)
Remifentanil hydrochloride	inj 2 mg vial; 5 vials	\$41.80	\$18.00	Ultiva (GSK)	1%	1 September 2014	1 November 2014	Remifentanil-AFT (AFT)

7. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Ceftazidime	inj 500 mg vial; 1 vial	\$2.37	\$5.30	Fortum (GSK)	1%	1 August 2014	1 October 2014
Ciprofloxacin	tab 250 mg; 28 tablets, blister pack	\$2.20	\$1.75	Cipflox (Mylan)	1%	1 July 2014	1 September 2014
Ciprofloxacin	tab 500 mg; 28 tablets, blister pack	\$3.00	\$2.00	Cipflox (Mylan)	1%	1 July 2014	1 September 2014

Ciprofloxacin	tab 750 mg; 28 tablets, blister pack	\$5.15	\$3.75	Cipflox (Mylan)	1%	1 July 2014	1 September 2014
Exemestane	tab 25 mg; 30 tablets, blister pack	\$22.57	\$14.50	Aromasin (Pfizer)	1%	1 July 2014	1 September 2014
Lamivudine	oral liq 5 mg per ml; 240 ml, bottle	\$90.00	\$270.00	Zeffix (GSK)	1%	1 September 2014	1 November 2014
Paracetamol	oral liq 250 mg per 5 ml; 1,000 ml, bottle	\$6.70	\$4.35	Paracare Double Strength (API)	20%	1 July 2014	1 September 2014
Pravastatin	tab 20 mg; 30 tablets, blister pack	\$5.44	\$3.45	Cholvastin (Douglas)	1%	1 August 2014	1 October 2014
Pravastatin	tab 40 mg; 30 tablets, blister pack	\$9.28	\$6.36	Cholvastin (Douglas)	1%	1 August 2014	1 October 2014
Rizatriptan	tab orodispersible 10 mg; 30 tablets, blister pack	\$18.00	\$8.10	Rizamelt (Mylan)	1%	1 July 2014	1 September 2014
Zidovudine [AZT] with lamivudine	tab 300 mg with lamivudine 150 mg; 60 tablets, bottle	\$63.50	\$44.00	Alphapharm (Mylan)	1%	1 July 2014	1 September 2014

8. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Pack price	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Cyproterone acetate with ethinyloestradiol	tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets; 168 tablets, blister pack (6 x 21 active tablets and 6 x 7 placebo tablets, blister pack)	\$5.36	Ginet (Rex Medical)	1%	1 October 2014	1 December 2014
Potassium iodate	tab 253 mcg (150 mcg elemental iodine); 90 tablets, bottle	\$3.65	NeuroTabs (AFT)	1%	1 October 2014	1 December 2014

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2013/14 Invitation to Tender, dated 07 November 2013:

2013/14 Invitation to Tender

Chemical Name	Line Item	Chemical Name	Line Item
Adapalene	Crn 0.1%	Adapalene	Gel 0.1%
Ciprofloxacin	Oral liq 100mg per ml	Ciprofloxacin	Oral liq 50mg per ml
Glyceryl trinitrate	Tab 500 mcg - 600 mcg	Nifedipine	Cap 5 mg
Pamidronate disodium *	Inj 3 mg per ml, 5 ml *	Pancreatic enzyme	Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease
Pancreatic enzyme	Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease	Pancreatic enzyme	Cap EC 25,000 BP u lipase, 22,500 BP u amylase, 1,250 BP u protease
Pancreatic enzyme	Powder	Verapamil hydrochloride	Tab long-acting 120 mg
Verapamil hydrochloride	Tab long-acting 240 mg		
Note: pamidronate disodium- inj 3 mg per ml, 5 ml will be delisted from 1 December 2014 in Section B of the Pharmaceutical Schedule and 1 September 2014 from Part II of Section H of the Pharmaceutical Schedule.			

PHARMAC has resolved not to award tenders for Hospital Supply Status for the following products listed in the 2013/14 Invitation to Tender, dated 07 November 2013:

Chemical Name	Line Item	Chemical Name	Line Item
Paracetamol	Tab 500 mg	Ibuprofen	Tab 200 mg

For products included in the 2011/12 Invitation to Tender, 2012/13 or the 2013/14 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.